Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Death Dis ; 2: e150, 2011 Apr 28.
Article in English | MEDLINE | ID: mdl-21525937

ABSTRACT

We reported a relevant activity of the combination between sorafenib and octreotide long-acting release (LAR) in advanced hepatocellular carcinoma (HCC) patients. In this work, we have studied if oxidative stress in both serum and peripheral blood mononuclear cells (PBMC) and pERK activation status in PBMC could be predictive of response. In the 20 responsive patients, the decrease of reactive oxygen species levels was already detectable after 10 days (T10) from the beginning of sorafenib administration, and this effect was enhanced by the combined treatment with sorafenib+octreotide LAR (T21). This effect correlated with the modulation of superoxide dismutase (SOD) activity (physiological scavenger of O(2-)) and of serum nitric oxide (NO) levels. Sorafenib alone induced an increase of about 40% of NO levels and of about two-fold of SOD activity in responsive patients, and both effects were significantly potentiated by the combined treatment. We found a gradual reduction of Erk1/2 activity, as evaluated by cytofluorimetric analysis, in 15 responsive patients reaching about 50% maximal decrease at T21. On the other hand, in 17 resistant patients, Erk1/2 activity was about 80% increased at T21. The determination of both the oxidative stress status and pERK activity in PBMC has high value in the prediction of response to sorafenib+octreotide therapy in HCC patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/blood , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Mitogen-Activated Protein Kinase 1/blood , Mitogen-Activated Protein Kinase 3/blood , Oxidative Stress , Benzenesulfonates/administration & dosage , Carcinoma, Hepatocellular/metabolism , Delayed-Action Preparations/administration & dosage , Drug Resistance, Neoplasm , Female , Humans , Leukocytes, Mononuclear/metabolism , Liver Neoplasms/metabolism , Male , Niacinamide/analogs & derivatives , Nitric Oxide/blood , Octreotide/administration & dosage , Phenylurea Compounds , Phosphorylation , Pyridines/administration & dosage , Reactive Oxygen Species/blood , Sorafenib , Superoxide Dismutase/blood , Treatment Outcome
2.
Behav Brain Res ; 198(1): 37-44, 2009 Mar 02.
Article in English | MEDLINE | ID: mdl-19041899

ABSTRACT

The excitatory amino acids (EAA) L-glutamate (L-Glu), L-aspartate (L-Asp) and D-aspartate (D-Asp) are thought to play a neurotransmitter/neuromodulator role in neuronal communications. Recently, a high level of EAA L-Glu, D- and L-Asp isomers has been found in the forebrain of Naples high-excitability (NHE) rat line that models the mesocortical variant of Attention-Deficit Hyperactivity Disorder (ADHD). The aim of this study was to assess the functions of D-Asp using two forms, i.e. free D-Asp or D-Asp diethyl ester (DEE) as prodrug, on brain and behaviour. Thus, prepuberal rats were given, for two weeks daily, an i.p. injection of D-Asp or DEE or vehicle. Then rats were exposed to two spatial novelties i.e. Làt and radial Olton maze. Behaviour was monitored for indices of activity, non-selective attention (NSA), selective spatial attention (SSA) and emotional reactivity. L-Glu and D- and L-Asp were detected by HPLC in cognitive and non-cognitive brain areas such as prefrontal cortex, striatum, hippocampus and hypothalamus. Results indicate that subchronic D-Asp or DEE (i) reduced EAA levels in the NHE and increased it in the random-bred controls (NRB) rats, (ii) in the Làt-maze D-Asp increased horizontal activity in NHE but DEE decreased it in NRB rats, (iii) in the Olton maze D-Asp and DEE decreased vertical activity in NHE and NRB rats respectively, (iv) D-Asp impaired attention only in NRB decreasing number of arms visited before first repetition. Therefore, data demonstrate differential effects of prepuberal subchronic D-Asp and DEE that may be related to different basal EAA levels in NHE and NRB rats.


Subject(s)
Aspartic Acid/analogs & derivatives , Aspartic Acid/pharmacology , Attention Deficit Disorder with Hyperactivity/metabolism , Behavior, Animal , Excitatory Amino Acids/metabolism , Prodrugs/pharmacology , Prosencephalon/metabolism , Animals , Aspartic Acid/administration & dosage , Attention/drug effects , Attention Deficit Disorder with Hyperactivity/drug therapy , Attention Deficit Disorder with Hyperactivity/physiopathology , Behavior, Animal/drug effects , Chromatography, High Pressure Liquid , Corpus Striatum/metabolism , Disease Models, Animal , Emotions/drug effects , Emotions/physiology , Exploratory Behavior/drug effects , Glutamic Acid/metabolism , Hippocampus/metabolism , Hypothalamus/metabolism , Injections, Subcutaneous , Maze Learning/drug effects , Motor Activity/drug effects , Prefrontal Cortex/metabolism , Prodrugs/administration & dosage , Prodrugs/metabolism , Prosencephalon/drug effects , Rats , Rats, Inbred Strains , Space Perception/drug effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...